STAT+: Radiopharma companies merge after one receives surprise FDA rejection — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Telix Pharmaceuticals will acquire all shares of privately held ITM Isotope Technologies Munich SE in a radiopharmaceuticals merger worth at least $1.65 billion.
- ITM shareholders stand to receive an additional $700 million in contingent payment if ITM's lead drug meets stated regulatory and sales goals.
- Novartis currently dominates the radiopharmaceuticals field, having launched two such treatments in 2018 and 2022.
- Radiopharmaceuticals deliver radioactive isotopes directly to cancer cells, the mechanism underlying both companies' pipelines.
Why it matters: The $1.65 billion acquisition installs Telix-ITM as the most credible challenger to Novartis in radiopharmaceuticals, a field Novartis seeded with two approvals in 2018 and 2022. ITM shareholders collect the full $700 million earnout only if the lead drug clears regulatory and sales milestones, transferring product risk onto Telix's balance sheet.
Ask SkimNews
